GENEBIOTECH CO. ,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,955 KRW | -0.50% |
|
-0.38% | -9.29% |
| Sales 2022 | 82.76B 59.67M 81.68M | Sales 2023 | 79.48B 57.3M 78.44M | Capitalization | 37.54B 27.07M 37.05M |
|---|---|---|---|---|---|
| Net income 2022 | 1.52B 1.1M 1.5M | Net income 2023 | 2.59B 1.87M 2.56M | EV / Sales 2022 | 0.38 x |
| Net cash position 2022 | 3.06B 2.21M 3.02M | Net cash position 2023 | 9.51B 6.86M 9.39M | EV / Sales 2023 | 0.35 x |
| P/E ratio 2022 |
22.6
x | P/E ratio 2023 |
14.5
x | Employees | 39 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 70.76% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.50% | ||
| 1 week | -0.38% | ||
| Current month | +0.76% | ||
| 1 month | -1.12% | ||
| 3 months | -5.16% | ||
| 6 months | -8.77% | ||
| Current year | -9.29% |
1 week
3 955.00
4 365.00
1 month
3 900.004 365.00
Current year
3 775.004 745.00
1 year
3 775.005 430.00
3 years
3 650.007 720.00
5 years
3 180.008 380.00
10 years
2 590.0011 100.00
| Managers | Title | Age | Since |
|---|---|---|---|
Chan-Ho Lee
CEO | Chief Executive Officer | 60 | - |
Joo-Sun Park
BRD | Director/Board Member | 49 | - |
Won-Tak Cho
BRD | Director/Board Member | 55 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chan-Ho Lee
CEO | Chief Executive Officer | 60 | - |
Jeong-Seon Kang
PRN | Corporate Officer/Principal | 60 | - |
Won-Tak Cho
BRD | Director/Board Member | 55 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-21 | 3,955 | -0.50% | 25,370 |
| 24-06-20 | 3,975 | -0.13% | 26,013 |
| 24-06-19 | 3,980 | -1.00% | 64,023 |
| 24-06-18 | 4,020 | -2.43% | 84,419 |
| 24-06-17 | 4,120 | +3.78% | 397,325 |
End-of-day quote Korea S.E., June 20, 2024
More quotes
GeneBioTechCo.,Ltd. is a company mainly engaged in the production and sale of feed additives and animal drugs. Along with subsidiaries, the Company operates its business through two segments. The Additive segment is involved in the manufacturing and sale of fermented products and bio starches. The Animal Drug segment is involved in the manufacturing and sale of livestock and fish medicine. The main products include vitamins, minerals, antibiotics, nutrients, immune stimulators, digestion and absorption promoters, among others. The Company distributes its products within the domestic market and to overseas markets, including America.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -9.29% | 24.5M | |
| +51.63% | 796B | |
| +41.51% | 628B | |
| -5.10% | 358B | |
| +19.90% | 331B | |
| +9.95% | 301B | |
| +17.66% | 244B | |
| +3.39% | 228B | |
| +10.75% | 214B | |
| +6.99% | 165B |
- Stock Market
- Equities
- A086060 Stock
